Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.
Industries
Nr. of Employees
medium (51-250)
Armata Pharmaceuticals, Inc.
5005 McConnell Ave, Los Angeles, CA 90066
Awards
Multi-Topic Prototype Project - U.S. Army Medical Research and Materiel Command (USAMRMC) Multitopic
Development of AP-SA02: A Novel Bacteriophage Therapeutic for Targeted Treatment of Staphylococcus aureus Bacteremia, including Drug Resistant Forms
Funding (ceiling)
$26,201,264.38
Award Year
2020
Patents
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
2025-04-08 • US-12268720-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
2025-03-04 • US-12239677-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
2023-05-23 • US-11654166-B2
View Details
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
2025-04-08 • US-12268720-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
2025-03-04 • US-12239677-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
2023-05-23 • US-11654166-B2
View DetailsProducts
Clinical‑stage inhaled phage cocktail for Pseudomonas aeruginosa pulmonary infection
Sterile liquid phage cocktail formulated for nebulized inhalation to treat chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis or bronchiectasis; evaluated in randomized Phase 1b/2a and Phase 2 studies with safety, lung delivery and exploratory bacterial load endpoints.
Phage cocktail candidate for acute Pseudomonas aeruginosa pneumonia
Phage cocktail in development for hospital‑acquired and ventilator‑associated Pseudomonas aeruginosa pneumonia; selected from clinical isolate collections and optimized for acute pulmonary physiology.
Clinical‑stage intravenous phage cocktail for Staphylococcus aureus bloodstream and device‑associated infections
High‑purity intravenous phage product composed of lytic phages active against a broad set of Staphylococcus aureus clinical isolates, evaluated as adjunctive therapy for bacteremia and studied for prosthetic joint infection indications in randomized Phase 1b/2a trials.
Clinical‑stage inhaled phage cocktail for Pseudomonas aeruginosa pulmonary infection
Sterile liquid phage cocktail formulated for nebulized inhalation to treat chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis or bronchiectasis; evaluated in randomized Phase 1b/2a and Phase 2 studies with safety, lung delivery and exploratory bacterial load endpoints.
Phage cocktail candidate for acute Pseudomonas aeruginosa pneumonia
Phage cocktail in development for hospital‑acquired and ventilator‑associated Pseudomonas aeruginosa pneumonia; selected from clinical isolate collections and optimized for acute pulmonary physiology.
Clinical‑stage intravenous phage cocktail for Staphylococcus aureus bloodstream and device‑associated infections
High‑purity intravenous phage product composed of lytic phages active against a broad set of Staphylococcus aureus clinical isolates, evaluated as adjunctive therapy for bacteremia and studied for prosthetic joint infection indications in randomized Phase 1b/2a trials.
Expertise Areas
- Phage therapeutic discovery and development
- Synthetic biology and viral genome engineering
- cGMP biomanufacturing and CMC for biologics
- Formulation development for inhaled and intravenous delivery
Key Technologies
- Next‑generation sequencing (NGS)
- Comparative genomics
- Bioinformatics and sequencing databases
- Synthetic biology for viral genome engineering
Key People
Chief Executive Officer
Chief Business Officer
Senior Vice President of Finance
Vice President of Operations
Vice President of Quality
Regulatory Strategy and Operations
Chief Executive Officer
Chief Business Officer
Senior Vice President of Finance
Vice President of Operations
Vice President of Quality
Regulatory Strategy and Operations
Featured In Technology Showcase
Development of a Novel Bacteriophage Therapeutic for Targeted Treatment of Staphylococcus aureus Bacteremia, Including Drug Resistant Forms.
Staphylococcus aureus infection is a major military health issue. Military personnel, including those on land and at sea, are at heightened risk of infection because the operational environment often involves close quarters and shared equipment for prolonged periods of time. AP-SA02, a novel bacteriophage therapeutic, is being developed by Armata Pharmaceuticals to treat military and civilian patients with S. aureus bacteremia.